Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 10Melanoma 9Carcinoma, Non-Small-Cell Lung 8Neoplasms 6Neoplasm Metastasis 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Ovarian Neoplasms 4Mouth Neoplasms 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Laryngeal Neoplasms 3Colonic Neoplasms 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Kidney Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma 2

Interventions

Cisplatin 24pembrolizumab 23Magnetic Resonance Spectroscopy 19Specimen Handling 16Radiotherapy, Intensity-Modulated 12Carboplatin 12Cetuximab 111,2-diaminocyclohexaneplatinum II citrate 10Platinum 9Paclitaxel 9Radiotherapy 6Radiation 6Fluorouracil 6Biopsy 5Taxes 4Nivolumab 4Docetaxel 4(225)Ac-DOTA-c(RGDyK) 4X-Rays 3Pemetrexed 3Fluorodeoxyglucose F18 3reolysin 2pralsetinib 2ipatasertib 2cemiplimab 2atezolizumab 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Image-Guided 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × cemiplimab × Head & Neck × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡